Amgen Just Bet on a Computer That Doesn't Fully Exist Yet
Quantinuum, a quantum computing company backed by Amgen and valued at $10 billion, just filed for what could be the largest quantum IPO ever. The real story: Amgen is betting quantum computers can fundamentally redesign how drugs get discovered.
The Biggest IPO You've Never Heard Of
Somewhere between science fiction and your next prescription, there's a computer that could redesign how drugs get made. And it's about to go public.
Quantinuum, a quantum computing company backed by Amgen, JPMorgan, NVIDIA, and Mitsui, has filed to list on the Nasdaq under the ticker QNT. Its last private valuation? A cool $10 billion. If the IPO prices anywhere near that neighborhood, it would be the largest quantum computing IPO ever.
But the real story isn't the ticker symbol. It's what Amgen thinks this machine can do for drug discovery.
Quantum Computing, Without the PhD
Let's get this out of the way: quantum computing is confusing. Classical computers (the one you're reading this on) process information in bits, which are either a 0 or a 1. Quantum computers use "qubits," which can be both 0 and 1 at the same time. Think of it like flipping a coin: a regular computer can only see heads or tails. A quantum computer can see the coin while it's still spinning.
Why does that matter for drugs? Because molecules are quantum objects. The way proteins fold, the way a drug binds to a target, the way electrons dance around atoms: all of it follows quantum rules. Classical computers have to approximate that behavior. Quantum computers can simulate it natively. It's the difference between reading a recipe and actually tasting the food.
Quantinuum specializes in trapped-ion quantum computers, which are considered among the most accurate commercial systems available. Accurate enough, in fact, that DARPA advanced the company to Stage B of its Quantum Benchmarking Initiative.
Amgen's Quantum Playbook
Amgen isn't just writing checks here. The pharma giant participated in Quantinuum's $300 million equity round in 2024 and came back for the $600 million raise in 2025. That's not passive interest; that's conviction.
The two companies are actively collaborating on a specific problem: for designing new therapeutic proteins. In plain English, they're using quantum computing to predict how well small protein fragments latch onto biological targets. Getting that prediction right early in the process could save years of lab work and hundreds of millions of dollars.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
improving peptide binding classification
Amgen's VP of R&D Technology and Innovation, Alan Russell, has described the partnership as Amgen's "third strategic push" into quantum for drug discovery.
That language is telling. This isn't a toe-dip. It's a cannonball.
Why Now?
The quantum computing market in drug discovery is growing fast. But the honest truth is that quantum hardware still has serious limitations: limited qubit counts, noise, and scaling challenges that make full-scale drug simulations difficult today.
So why are smart pharma companies investing now? Because the race isn't about today. It's about being first in line when the hardware catches up.
Consider the analogy of buying beachfront property before the highway gets built. The land isn't worth much yet, but whoever owns it when traffic arrives wins big. Amgen is buying beachfront.
A June 2025 collaboration between IonQ and AstraZeneca (with help from AWS and NVIDIA) demonstrated a 20x speed improvement in molecular simulation workflows. That's not theoretical. That's a published result showing quantum-enhanced approaches already outperforming classical methods in specific tasks.
Hybrid approaches, combining quantum algorithms with traditional computing, have shown particular promise. In a review of 15 empirical studies, 13 reported measurable gains from the hybrid model. The technology isn't replacing classical computing overnight; it's augmenting it where it matters most.
A Quantum Gold Rush on Wall Street
Quantinuum isn't filing into a vacuum. The public market is suddenly hungry for quantum stocks.
Xanadu, a photonic quantum computing company, went public in March 2026 via a SPAC merger. Infleqtion, which builds neutral-atom quantum systems, completed its SPAC merger at an $1.8 billion valuation. Horizon Quantum listed on the Nasdaq on March 20 with about $619 million in post-merger equity.
Some of these companies have seen jaw-dropping stock performance. Rigetti posted a 1,000% one-year return at its peak. IonQ attracted buy ratings from 10 of 17 covering analysts.
But there's an important caveat: most of these companies are pre-revenue or barely profitable. The valuations are built on potential, not earnings. That makes Amgen's involvement especially significant. When one of the world's largest biopharma companies keeps writing checks, it signals something beyond hype.
The Amgen Ecosystem Strategy
Zoom out, and Quantinuum fits neatly into a broader pattern. Amgen has been quietly assembling one of pharma's most formidable computational arsenals.
It starts with deCODE Genetics, the Icelandic human genetics powerhouse Amgen acquired in 2012 for $415 million. That dataset is essentially irreplaceable: decades of genomic data from a uniquely homogeneous population. It's the training data every AI company wishes it had.
Layered on top is Freyja, a purpose-built NVIDIA DGX SuperPOD supercomputer housed alongside the deCODE data. Amgen also announced a $600 million investment in a new science and innovation center at its Thousand Oaks headquarters in September 2025. And it signed a $1.9 billion deal (including milestones and royalties) with Generate Biomedicines for AI-designed protein therapeutics.
Quantum computing is the next layer in this stack. Amgen isn't betting on any single technology. It's building an ecosystem where genetics, AI, supercomputing, and quantum all feed into the same drug discovery engine.
The $10 Billion Question
Quantinuum's IPO will test whether public investors share Amgen's conviction. The S-1 was filed confidentially in February 2026, with JPMorgan and Morgan Stanley leading the offering. No pricing details have been disclosed yet.
At $10 billion, Quantinuum would dwarf every other public quantum company. That's a bold number for a sector where commercial revenue remains thin. But it's also a company with Honeywell's engineering DNA (Quantinuum was formed in 2021 from Honeywell's quantum hardware spin-off merged with a U.K. software firm), a roster of blue-chip investors, and real pharma collaborations producing real data.
The quantum computing market for healthcare is projected to grow rapidly in the coming years. That trajectory either justifies the premium or makes this the most expensive lottery ticket in tech. Probably a little of both.
For Amgen, the math is simpler. If quantum computing shaves even a year off the drug development timeline for one blockbuster molecule, the return on a few hundred million in investment would be enormous. The average cost to bring a drug to market exceeds $2 billion. Quantum doesn't need to revolutionize everything. It just needs to make one expensive process significantly cheaper.
And for the rest of us watching from the sidelines? Keep an eye on that ticker: QNT. The future of drug discovery might just depend on a coin that never stops spinning.
Funding & Financings4 min read
The Pill That Could Rescue Myeloma Patients After Everything Else Fails
CellCentric just closed Europe's largest private biotech raise of 2026 to fund a first-in-class oral pill for myeloma patients who've failed everything else. The Phase 2 data show response rates double or triple the competition, and the investor list includes a very interesting pharma name.
